Blog
RSS FeedPosted by Michael Wonder on 28 Mar 2023
iOnctura awarded UK's MHRA Innovation Passport for entry into innovative licensing and access pathway
28 March 2023 - iOnctura today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, ...
Posted by Michael Wonder on 12 Mar 2023
The value of medical innovation versus industry rewards
10 March 2023 - This article provides systematic evidence on the share of the value of health generated by drugs and ...
Posted by Michael Wonder on 10 Mar 2023
Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices.
10 March 2023 - By law, Medicare will have to take a medication’s efficacy and its research and development costs ...
Posted by Michael Wonder on 27 Feb 2023
Areteia Therapeutics granted ILAP designation from UK MHRA for oral dexpramipexole for eosinophilic asthma
23 February 2023 - Areteia Therapeutics today announced that the UK’s MHRA has granted an Innovation Passport under the Innovative Licensing ...
Posted by Michael Wonder on 16 Feb 2023
Testing a hypothesis: can we promote both innovation and affordability of drugs?
16 February 2023 - This week’s announcement by the CMS to test new payment models which promote both pharmaceutical access and ...
Posted by Michael Wonder on 14 Feb 2023
Verve Therapeutics announces VERVE-101 awarded Innovation Passport by the UK MHRA for the treatment of heterozygous familial hypercholesterolaemia
14 February 2023 - Verve Therapeutics today announced that VERVE-101 has been awarded the Innovation Passport for the treatment of ...
Posted by Michael Wonder on 11 Feb 2023
Digital health predictions: uncertainty will trigger innovation in 2023
7 February 2023 - It was an interesting year for digital health. ...
Posted by Michael Wonder on 21 Jan 2023
Sources of innovation in gene therapies - approaches to achieving affordable prices
21 January 2023 - Gene therapies are a fast growing area of innovation and potentially hold great promise for clinical care. ...
Posted by Michael Wonder on 21 Jan 2023
Novartis warns US plan to curb drug prices could hit key research
21 January 2023 - US Government plans to rein in drug prices could discourage work in some of Novartis' most ...
Posted by Michael Wonder on 17 Jan 2023
Innovative Medicines Canada proposes framework for innovative agreements for drug reimbursement
16 January 2023 - Pharmaceutical manufacturers in Canada often enter into product listing agreements, particularly with public payers, to facilitate their ...
Posted by Michael Wonder on 17 Jan 2023
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
16 January 2023 - Bayer has said it is shifting the focus of its pharmaceutical business to the US and ...
Posted by Michael Wonder on 12 Jan 2023
Intellia Therapeutics awarded Innovation Passport in the United Kingdom for NTLA-2002, an investigational genome editing treatment for hereditary angioedema
11 January 2023 - NTLA-2002 is a single dose genome editing therapeutic candidate designed to prevent angioedema attacks in people ...
Posted by Michael Wonder on 07 Dec 2022
An innovation surcharge to fund the repurposing of generic drugs
10 November 2022 - The use of generic drugs continues to increase, generating substantial savings for purchasers and improving affordable access ...
Posted by Michael Wonder on 29 Nov 2022
NICE’s new methods: putting innovation first, but at what cost?
28 November 2022 - Traditionally the gatekeeper to the NHS, NICE has increasingly reoriented its role towards facilitating access to innovative ...
Posted by Michael Wonder on 21 Nov 2022
New Quality Innovation Expert Group supports medicine innovation
21 November 2022 - The EMA has established a Quality Innovation Expert Group to support innovative approaches for the development, ...